ceperognastat   Click here for help

GtoPdb Ligand ID: 11953

Synonyms: LY-3372689 | LY3372689
PDB Ligand
Compound class: Synthetic organic
Comment: LY3372689 is a O-GlcNAcase (OGA) inhibitor that was developed by Eli Lilly as a tau modulator for Alzheimer's disease. Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting, and it is a chemical structure that is claimed in Eli Lilly's patent WO2018140299A1 [1]. Information from clinical trial records indicates that LY3372689 is administered orally. The structure for LY3372689 matches that for the INN ceperognastat (proposed list 132, Feb. 2025).
Functionally, O-GlcNAcase inhibition is proposed to enhance tau O-GlcNAcylation, with the effect of out-competing the phosphorylation that potentiates tau aggregation.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 121.62
Molecular weight 383.14
XLogP 0.66
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)Nc1nc(c(s1)CN1CC[C@@H](C[C@@H]1C)OCc1noc(n1)C)F
Isomeric SMILES C[C@H]1C[C@H](CCN1Cc1c(F)nc(NC(=O)C)s1)OCc1noc(C)n1
InChI InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)/t9-,12-/m0/s1
InChI Key FRVXHWNHGWUTQO-CABZTGNLSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Dreyfus NJF, Lindsay-Scott PJ. (2018)
N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor.
Patent number: WO2018140299A1. Assignee: Eli Lilly And Company. Priority date: 27/01/2017. Publication date: 02/08/2018.
2. Fleisher AS, Munsie L, Mancini M, Cheng YJ, Guo J, Nuthall H, Otero DS, Kotari V, Kielbasa W, Hutton M et al.. (2026)
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
JAMA, 336 (12): 1017-1028. [PMID:42441396]
3. Meade J, Mesa H, Alamgir S, Bieniecka I, Liu L, Zhang Q. (2026)
Synaptic toxicity of OGA inhibitors and the failure of ceperognastat.
J Prev Alzheimers Dis, 13 (2): 100456. [PMID:41478829]